文献速递肺栓塞与肺血管病肺结节与肺癌

癌症合并偶发肺栓塞患者抗凝治疗期间及停药后的结局

Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism.
PubMed 文献 · Eur Respir J · 2016-09-22

基于RIETE注册研究,比较癌症合并偶发肺栓塞患者抗凝期间与停药后的大出血及症状性肺栓塞发生率。抗凝期间(平均235天)大出血发生率高于症状性肺栓塞(10.1 vs 3.17事件/100患者年),致死性出血也高于致死性肺栓塞;停药后(平均随访117天)大出血低于症状性肺栓塞(3.00 vs 8.37事件/100患者年),但致死性事件无差异。提示该类患者抗凝治疗的风险/获益比不确定,需进一步研究。

要点

  • 癌症偶发肺栓塞抗凝期间大出血风险高于症状性肺栓塞复发。
  • 抗凝期间致死性出血率高于致死性肺栓塞率。
  • 停药后症状性肺栓塞复发风险高于大出血,但致死性事件无差异。

核心结论

  • 癌症合并偶发肺栓塞患者抗凝治疗的风险/获益比不确定,需进一步研究评估。

研究设计与样本

  • 基于RIETE注册研究,纳入截至2016年3月的715例癌症合并偶发肺栓塞患者。
  • 比较抗凝治疗期间(平均235天)及停药后(平均随访117天)的大出血和症状性肺栓塞发生率。

主要发现

  • 抗凝期间大出血发生率为10.1(95%CI 7.48-13.4)事件/100患者年,高于症状性肺栓塞的3.17(95%CI 1.80-5.19)。
  • 抗凝期间致死性出血发生率为2.66(95%CI 1.44-4.52)死亡/100患者年,高于致死性肺栓塞的0.66(95%CI 0.17-1.81)。
  • 停药后大出血发生率为3.00(95%CI 1.10-6.65)事件/100患者年,低于症状性肺栓塞的8.37(95%CI 4.76-13.7)。
  • 停药后致死性事件均为1例死亡,无差异。

临床怎么用

  • 对癌症合并偶发肺栓塞患者抗凝治疗时,需密切监测出血风险,尤其抗凝期间。
  • 停药后仍需警惕症状性肺栓塞复发。

局限性

  • 为注册研究,可能存在选择偏倚和未测量混杂因素。
  • 抗凝方案及停药决策未详细说明,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current guidelines suggest treating cancer patients with incidental pulmonary embolism comparably to patients with symptomatic pulmonary embolism.We used the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry to compare the rate of major bleeding and symptomatic pulmonary embolism during the course of anticoagulation and after its discontinuation in cancer patients with incidental pulmonary embolism.As of March 2016, 715 cancer patients with incidental pulmonary embolism had been enrolled in RIETE. During the course of anticoagulant therapy (mean 235 days), the rate of major bleeding was higher than the rate of symptomatic pulmonary embolism (10.1 (95% CI 7.48-13.4) versus 3.17 (95% CI 1.80-5.19) events per 100 patient-years, respectively), and the rate of fatal bleeding was higher than the rate of fatal pulmonary embolism (2.66 (95% CI 1.44-4.52) versus 0.66 (95% CI 0.17-1.81) deaths per 100 patient-years, respectively). After discontinuing anticoagulation (mean follow-up 117 days), the rate of major bleeding was lower than the rate of symptomatic pulmonary embolism (3.00 (95% CI 1.10-6.65) versus 8.37 (95% CI 4.76-13.7) events per 100 patient-years, respectively); however, there were no differences in the rate of fatal events at one death each.The risk/benefit ratio of anticoagulant therapy in cancer patients with incidental pulmonary embolism is uncertain and must be evaluated in further studies.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Peris M, Jiménez D, Maestre A, et al. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Eur Respir J. 2016. PMID: 27660517. doi:10.1183/13993003.00779-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。